©2022 Stanford Medicine
PCSK9 Inhibition After Heart Transplantation
Recruiting
I'm InterestedTrial ID: NCT03537742
Purpose
The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab
when administered early after heart transplantation (HT).The main objective of this project
is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when
given early after HT.
Official Title
PCSK9 Inhibition After Heart Transplantation
Stanford Investigator(s)
William Fearon, MD
Professor of Medicine (Cardiovascular Medicine)
Eligibility
Inclusion Criteria:
- Heart Transplant recipient
Exclusion Criteria:
- impaired liver function
Intervention(s):
biological: alirocumab
biological: placebo
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Study Team
650-724-2883